Improving outcomes for immunocompromised patients

Chimerix, a biopharmaceutical company in Durham, North Carolina, is developing innovative medicines to prevent and treat multiple, life-threatening viral infections in bone marrow transplant recipients and other people with weakened immune systems.

Like Comment
Page of
Go to the profile of Chimerix


Incorporated in 2000, Chimerix is a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. We believe that antivirals that could reduce the frequency of these and other DNA viruses and potentially avoid increasing the risk of other opportunistic infections could provide measurable clinical and pharmacoeconomic benefits for patients and the healthcare system. Through work to date, we see significant opportunities to apply the lipid conjugate technology to other disease categories that are also characterized by a need for effective treatments.

No comments yet.